These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38267451)

  • 41. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs.
    Lamine F; Lalubin F; Pitteloud N; Burnier M; Zanchi A
    Swiss Med Wkly; 2016; 146():w14282. PubMed ID: 26922155
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
    Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
    Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metformin: time to review its role and safety in chronic kidney disease.
    Tanner C; Wang G; Liu N; Andrikopoulos S; Zajac JD; Ekinci EI
    Med J Aust; 2019 Jul; 211(1):37-42. PubMed ID: 31187887
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD.
    Allegretti AS; Zhang W; Zhou W; Thurber TK; Rigby SP; Bowman-Stroud C; Trescoli C; Serusclat P; Freeman MW; Halvorsen YC
    Am J Kidney Dis; 2019 Sep; 74(3):328-337. PubMed ID: 31101403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparative effectiveness of metformin versus sulfonylureas on kidney function decline or death among patients with reduced kidney function: a retrospective cohort study.
    Hung AM; Hackstadt AJ; Griffin MR; Grijalva CG; Greevy RA; Roumie CL
    CMAJ Open; 2023; 11(1):E77-E89. PubMed ID: 36720491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
    Chu PY; Hackstadt AJ; Chipman J; Griffin MR; Hung AM; Greevy RA; Grijalva CG; Elasy T; Roumie CL
    Diabetes Care; 2020 Jul; 43(7):1462-1470. PubMed ID: 32327421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of HuoxueJiangtang decoction alone or in combination with metformin on renal function and renal cortical mRNA expression in diabetic nephropathy rats.
    Liu X; Liu D; Shuai Y; Li H; Zhao H; Qu X; Chu S; Zhang X
    Pharm Biol; 2020 Dec; 58(1):1123-1130. PubMed ID: 33191822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review.
    Crowley MJ; Diamantidis CJ; McDuffie JR; Cameron CB; Stanifer JW; Mock CK; Wang X; Tang S; Nagi A; Kosinski AS; Williams JW
    Ann Intern Med; 2017 Feb; 166(3):191-200. PubMed ID: 28055049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Diabetic retinopathy may predict the renal outcomes of patients with diabetic nephropathy.
    Zhang J; Wang Y; Li L; Zhang R; Guo R; Li H; Han Q; Teng G; Liu F
    Ren Fail; 2018 Nov; 40(1):243-251. PubMed ID: 29633887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription-medication sharing among family members: an unrecognized cause of a serious drug adverse event in a patient with impaired renal function.
    Makówka A; Zawiasa A; Nowicki M
    Clin Nephrol; 2015 Mar; 83(3):196-200. PubMed ID: 24691009
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral hypoglycaemic agents and the development of non-fatal cardiovascular events in patients with type 2 diabetes mellitus.
    Hung YC; Lin CC; Wang TY; Chang MP; Sung FC; Chen CC
    Diabetes Metab Res Rev; 2013 Nov; 29(8):673-9. PubMed ID: 23956007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Use of metformin in diseases of aging.
    Miles JM; Rule AD; Borlaug BA
    Curr Diab Rep; 2014 Jun; 14(6):490. PubMed ID: 24752835
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic kidney disease in type 2 diabetes: lessons from the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study.
    Pugliese G; Solini A; Bonora E; Fondelli C; Orsi E; Nicolucci A; Penno G;
    Nutr Metab Cardiovasc Dis; 2014 Aug; 24(8):815-22. PubMed ID: 24780515
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study.
    Banerji MA; Purkayastha D; Francis BH
    Diabetes Res Clin Pract; 2010 Nov; 90(2):182-90. PubMed ID: 20655609
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metformin Use Is Associated with Fewer Complications in Patients with Type-2 Diabetes Undergoing Total Knee Arthroplasty: A Propensity Score-Matched Analysis.
    Wilson JM; Farley KX; Broida SE; Bradbury TL; Guild GN
    J Bone Joint Surg Am; 2021 Apr; 103(7):601-608. PubMed ID: 33787554
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study.
    Lee KT; Yeh YH; Chang SH; See LC; Lee CH; Wu LS; Liu JR; Kuo CT; Wen MS
    Medicine (Baltimore); 2017 Jul; 96(28):e7507. PubMed ID: 28700501
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metformin in chronic kidney disease: time for a rethink.
    Heaf J
    Perit Dial Int; 2014 Jun; 34(4):353-7. PubMed ID: 24711640
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
    Engel SS; Suryawanshi S; Stevens SR; Josse RG; Cornel JH; Jakuboniene N; Riefflin A; Tankova T; Wainstein J; Peterson ED; Holman RR;
    Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.